Teikoku Pharma Usa, Inc.

Alza Corporation

Henkel Ag & Company, Kgaa

Teikoku Seiyaku Co., Ltd.

Jianye Wen

Amit K Jain

Richard D Hamlin

Jutaro Shudo

Paul B Foreman

Eric N Silverberg

Allison Luciano

Eli J Goldman

Amit Jain

Bret Berner

Robert M Gale

Jay Douglas Audett

Adchara Pongpeerapat

John Michael Newsam

Edward Thomas Kisak

Servet Buyuktimkin

Nadir Buyuktimkin

Jay Audette

Russell Haynes

Susan Meier-Davis

Asha Sunkara

Richard Hamlin

Aspects of the invention include topical naloxone compositions for locally delivering naloxone to the skin of a subject. Topical compositions according to certain embodiments are storage stable non-aqueous topical compositions that include naloxone free base and a non-aqueous vehicle, wherein the compositions are substantially free of naloxone N-oxide. Also provided are methods of using the topical compositions to locally deliver naloxone to a subject, as well as kits containing the topical naloxone compositions.

Topical naloxone compositions and methods for using the same

Aspects of the invention include extended transdermal delivery devices for delivering buprenorphine to a subject for an extended period of time, where the transdermal delivery devices include buprenorphine, an &#x3b1;-hydroxy acid and a pressure sensitive adhesive. In certain instances, buprenorphine, &#x3b1;-hydroxy acid and the pressure sensitive adhesive are provided as a single matrix layer formulation. Also provided are methods of using the subject extended transdermal delivery devices, as well as kits containing the extended transdermal delivery device.

Extended buprenorphine transdermal delivery compositions and methods for using the same

Aspects of the invention include methods for applying to a subject a transdermal delivery device configured to deliver a non-sedative amount of a dexmedetomidine composition. In practicing methods according to certain embodiments, a non-sedative amount of a dexmedetomidine composition is transdermally applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver a non-sedative amount of dexmedetomidine to a subject. Also provided are transdermal delivery devices having a non-sedative amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.

Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine

Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix which includes the propynylaminoindan, a pressure sensitive adhesive that includes an acrylate copolymer and a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.

Propynylaminoindan transdermal compositions

Aspects of the invention include methods of treating ADHD, anxiety or insomnia by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver an amount of dexmedetomidine to a subject diagnosed as having ADHD, anxiety or insomnia. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine sufficient to treat ADHD, anxiety or insomnia in the subject. Also provided are transdermal delivery devices configured to deliver an amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.

Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions

Aspects of the invention include transdermal delivery devices for delivering dexmedetomine to a subject, where the transdermal delivery devices include a single layer matrix dexmedetomine composition. Transdermal delivery devices according to certain embodiments include dexmedetomidine and a pressure sensitive adhesive provided as a single layer formulation. Also provide are methods of using the subject transdermal delivery devices to deliver dexmedetomidine to a subject, as well as kits containing the transdermal delivery devices.

Dexmedetomidine transdermal delivery devices and methods for using the same

Methods of treating skin neoplasms using a monoamine oxidase inhibitor, e.g., a propynylaminoindan (such as rasagiline) are provided. Pharmaceutical compositions and kits comprising monoamine oxidase inhibitors are also provided.

Methods for the treatment of skin neoplasms

Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix of the propynylaminoindan in a pressure sensitive adhesive comprising a carboxylated polymer. In some instances, the matrix further includes a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.

The invention provides transdermal delivery systems, medical kits, and methods for using the transdermal delivery systems and kits for medical applications, such as delivery of contraceptive agents to control fertility.

Compositions and methods for transdermal delivery of hormones and other medicinal agents

A polyacrylate formulation suitable for delivery of drug to through a body surface of an individual. By loading the drug and permeation enhancers at a high concentration into a polyacrylate proadhesive that has inadequate adhesive properties for typical adhesive application on the skin, a formulation with desirable adhesive characteristics and effective therapeutic properties can be made. The proadhesive has higher glass transition temperature than typical pressure sensitive adhesives.

High enhancer-loading polyacrylate formulation for transdermal applications

Transdermal compositions are provided. Aspects of the transdermal compositions include: an active agent layer and a conversion layer, where the conversion layer includes a weak base and, optionally, a carboxylated component. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.

Growing community of inventors

Palo Alto, CA, United States of America

Jianye Wen